Evolutions in the treatment of nmCRPC

Posted on February 6, 2018 by Sitemaster

So we now have news reports and abstracts telling us what the top-line results of the SPARTAN trial and the PROSPER trial are in the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , | 17 Comments »

Phase III PROSPER trial of enzalutamide + ADT successful in nmCRPC

Posted on September 14, 2017 by Sitemaster

The Phase III PROSPER trial of enzalutamide + androgen deprivation therapy (ADT) versus a placebo + ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC) has apparently met its primary endpoint of improved metastasis-free survival. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , | 7 Comments »

Astellas/Medivation initiate Phase III trial of enzalutamide in nmCRPC

Posted on December 3, 2013 by Sitemaster

According to a media release issued by Astellas Pharma and Medivation earlier today, the companies have initiated a new Phase III clinical trial to investigate the efficacy and safety of enzalutamide in the management of non-metastatic (TxNxM0), castration-resistant prostate cancer (nmCRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 2 Comments »